NCT00224016 - Safety and Efficacy Study of Transdermal Oxybutynin to Treat Overactive Bladder With a Neurological Condition | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2004

Primary Completion Date

April 30, 2007

Study Completion Date

September 30, 2008

Conditions

Detrusor Hyperreflexia

Interventions

DRUG

Oxybutynin

1.3, 2.6, 3.9 mg/day transdermal

DRUG

Oxybutynin

5 to 15 mg/day immediate release or extended release tablets, or syrup

Trial Locations (23)

Watson Investigational Site, Little Rock

Watson Investigational Site, Orange County

Watson Investigational Site, San Diego

Watson Investigational Site, Denver

Watson Investigational Site, Washington D.C.

Watson Investigational Site, Detroit

Watson Investigational Site, Minneapolis

Watson Investigational Site, Jackson

Watson Investigational Site, Kansas City

Watson Investigational Site, St Louis

Watson Investigational Site, Voorhees Township

Watson Investigational Site, Albany

Watson Investigational Site, Buffalo

Watson Investigational Site, Poughkeepsie

Watson Investigational Site, Ashville

Watson Investigational Site, Durham

Watson Investigational Site, Columbus

Watson Investigational Site, Oklahoma City

Watson Investigational Site, Hershy

Watson Investigational Site, Dallas

Watson Investigational Site, Houston

Watson Investigational Site, Plano

Watson Investigational Site, Salt Lake City